engleski

Tamoxifen in trimodal therapy with cytotoxic drugs and hyperthermia in vivo significantly enhance therapeutic efficacy against B16-F10 melanoma

The results of systemic melanoma therapy have been mostly disappointing. Therefore, there is still a great need for strategies that can improve the existent chemotherapy options. The aim of this study was to investigate can the use of antiestrogen tamoxifen (TMX) and heat treatment in the combined therapy with well-known anticancer drugs (cisplatin, cDDP ; dacarbazine, DTIC ; and cyclophosphamide, CTX) enhance their therapeutic efficacy on mouse B16-F10 melanoma in vivo. Drugs were given intraperitoneally 15 min before the application of local hyperthermia (HT) and the tumor growth and mouse survival were followed. The HT alone resulted with a significant delay of tumor growth but the mouse survival was not affected. In bimodal combinations with HT, the all tested antitumor drugs significantly increased both tumor growth delay and mouse survival, with the largest increase recorded in the CTX+HT treatment, followed by the cDDP+HT and DTIC+HT bimodal treatments. In the dosage used, TMX alone did not show any inhibitory effect on B16-F10 melanoma in vivo. However, in the trimodal therapy with particular drug and HT, TXT potentiates the inhibitory effects of the respective bimodal treatments, especially that of CTX and HT. Thus, our results obtained on the mouse melanoma B16-F10 in vivo confirmed the enhanced therapeutic efficacy of the trimodal TXT, HT and anticancer drug combinations in melanoma treatment. Further studies should optimize the heat-drug time scheduling and drug doses that will result with the best possible therapeutic achievement for these trimodal therapy options.

anticancer drugs ; tamoxifen ; hyperthermia ; combined therapy ; melanoma B16-F10 ; in vivo ; mice

nije evidentirano